Linked Life Data

12470979

Source:http://linkedlifedata.com/resource/pubmed/id/12470979

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2002-12-9
pubmed:abstractText
Treatment of breast cancer requires a fully integrated multidisciplinary management as well as an ongoing dialogue with laboratory scientists. The growing amount of data generated by randomized clinical trials need to be interpreted by the clinicians and discussed with patients, so that treatment decisions might be better individualized. In early breast cancer, three consensus panels have been developed to help with this task: the Early Breast Cancer Trialists Collaborative Group or Oxford Overview, the NIH Consensus Conference on Adjuvant Therapy for Breast Cancer and the St. Gallen International Consensus Panel on the Treatment of Primary Breast Cancer. Nevertheless, even these panels leave us with a good deal of uncertainty about the optimal adjuvant systemic treatment of the disease, especially when it is classified as "endocrine non-responsive". The two most problematic issues regarding the management of endocrine non-responsive breast cancer are: (1) which fit woman should not be treated, with two major "to treat or not to treat" dilemmas, (a) women above 70 years of age, where available evidence is scant and co-morbid conditions more often come into the equation of benefit/risk, and (b) women who have very small invasive tumours (<1 cm); and (2) what is the optimal chemotherapy regimen (type, doses, schedule, timing and duration). The aim of this review is to examine these controversial issues. Two difficult clinical cases, which are representative of those frequently encountered in daily practice, will also be presented and discussed, with the help of a panel of 48 breast cancer experts from different regions of the world.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0305-7372
pubmed:author
pubmed:issnType
Print
pubmed:volume
28
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
275-90
pubmed:dateRevised
2006-4-24
pubmed:meshHeading
pubmed:year
2002
pubmed:articleTitle
Controversies in the adjuvant systemic therapy of endocrine-non-responsive breast cancer.
pubmed:affiliation
Chemotherapy Unit, Jules Bordet Institute, Brussels, Belgium.
pubmed:publicationType
Journal Article, Review